Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) is expected to be announcing its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter.
Oruka Therapeutics Stock Performance
NASDAQ:ORKA traded up $1.07 on Thursday, hitting $13.14. 108,735 shares of the company's stock were exchanged, compared to its average volume of 305,321. Oruka Therapeutics has a 52 week low of $10.95 and a 52 week high of $53.88. The stock has a market capitalization of $459.90 million, a P/E ratio of -2.09 and a beta of 0.81. The business has a 50-day simple moving average of $18.49.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, December 20th. Wedbush reiterated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Finally, Stifel Nicolaus started coverage on Oruka Therapeutics in a research note on Friday, October 11th. They issued a "buy" rating and a $49.00 price target on the stock. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $43.17.
Get Our Latest Stock Analysis on ORKA
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Featured Stories
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
